The Impact of Large-Scale Mergers on the Cervical Cancer Vaccines Market
Cervical cancer is a type of cancer that starts in the cervix, a cavity that can be found in the vagina, uterus, or vulva. It is a sexually transmitted disease caused by the human papilloma virus. There are several strains of this virus, and each has a different name relating to the part of the body in which it affects. Most cervical cancers are associated with human papillomavirus (HPV), a sexually transmitted infection. Extensive vaccination with the HPV vaccine may reduce the effects of cervical cancer across the world. HPV vaccines are vaccines that prevent infections by some varieties of the human papillomavirus. The two most commonly used vaccines are Gardasil and Cervarix, however, more vaccines are available now. Gardasil 9 is the U.S. FDA approved HPV vaccine and can be used for both girls and boys. HPV spread through sexual contact and is associated with most cases of cervical cancer. Increasing prevalence/incidence of cervical cancer across the world is expected to propel the growth of the cervical cancer vaccines market. For instance, around 140 new cases of cervical cancer in Minnesota in 2020, according to the American Cancer Society. Moreover, increasing government initiatives to increase awareness regarding cervical cancer and its treatments are expected to augment the growth of the cervical cancer vaccines market. For instance, the government of Rwanda (country in East Africa) planned to eradicate cervical cancer by 2020 by vaccinating all adolescents, especially girls, between the ages of 11 and 15. January is national cervical cancer awareness month. Read more @ https://www.coherentmarketinsights.com/market-insight/cervical-cancer-vaccines-market-2931
Cervical cancer is a type of cancer that starts in the cervix, a cavity that can be found in the vagina, uterus, or vulva. It is a sexually transmitted disease caused by the human papilloma virus. There are several strains of this virus, and each has a different name relating to the part of the body in which it affects. Most cervical cancers are associated with human papillomavirus (HPV), a sexually transmitted infection.
Extensive vaccination with the HPV vaccine may reduce the effects of cervical cancer across the world. HPV vaccines are vaccines that prevent infections by some varieties of the human papillomavirus. The two most commonly used vaccines are Gardasil and Cervarix, however, more vaccines are available now. Gardasil 9 is the U.S. FDA approved HPV vaccine and can be used for both girls and boys. HPV spread through sexual contact and is associated with most cases of cervical cancer.
Increasing prevalence/incidence of cervical cancer across the world is expected to propel the growth of the cervical cancer vaccines market. For instance, around 140 new cases of cervical cancer in Minnesota in 2020, according to the American Cancer Society. Moreover, increasing government initiatives to increase awareness regarding cervical cancer and its treatments are expected to augment the growth of the cervical cancer vaccines market. For instance, the government of Rwanda (country in East Africa) planned to eradicate cervical cancer by 2020 by vaccinating all adolescents, especially girls, between the ages of 11 and 15. January is national cervical cancer awareness month.
Read more @ https://www.coherentmarketinsights.com/market-insight/cervical-cancer-vaccines-market-2931
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CERVICAL<br />
CANCER VACCINES<br />
MARKET<br />
<strong>Market</strong> Size (2017)<br />
US$ 2,493.00 MN<br />
CAGR (2018–2026)<br />
12.1%<br />
© Coherent <strong>Market</strong> Insights. All Rights Reserved
Segmentati<strong>on</strong>s (Scope)<br />
• Gardasil<br />
• Gardasil 9<br />
• Cervarix<br />
• Hospitals<br />
• Clinics<br />
• Government Entities<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
Major Drivers<br />
Increasing<br />
prevalence <str<strong>on</strong>g>of</str<strong>on</strong>g><br />
cervical cancer<br />
worldwide<br />
Increasing<br />
government<br />
initiatives and<br />
programs<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
NORTH<br />
AMERICA<br />
<strong>Market</strong> Size<br />
US$ 1,089.4 MN<br />
CAGR<br />
12.3%<br />
Major Driver<br />
Increasing prevalence <str<strong>on</strong>g>of</str<strong>on</strong>g> cervical cancer in<br />
<strong>the</strong> U.S.<br />
Major Driver<br />
ASIA<br />
PACIFIC<br />
<strong>Market</strong> Size<br />
US$ 461.2 MN<br />
CAGR<br />
11.5%<br />
Increasing approval <str<strong>on</strong>g>of</str<strong>on</strong>g> cervical cancer vaccines<br />
by <strong>the</strong> regulatory bodies.<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
Major Players<br />
GlaxoSmithKline<br />
plc<br />
Merck & Co.<br />
Inc.<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
Global <strong>Cervical</strong> <strong>Cancer</strong> <strong>Vaccines</strong> <strong>Market</strong> (%)<br />
Analysis, By Product Type, 2018<br />
Gardasils Gardasils 9 Cervarix<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
Change language